Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement
Clinical trial NCT05926427 · UNKNOWN
Trial details
- NCT number
- NCT05926427
- Sponsor
- Ruijin Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-10
- Primary completion
- 2026-04-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.